'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson

Chris Gibson, Recursion CEO, joins 'Closing Bell Overtime' to talk drug development, quarterly earnings, tech integration in pharmaceuticals and more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: cnb.cx/2NGeIvi
» Subscribe to CNBC TV: cnb.cx/Subscri...
» Subscribe to CNBC: cnb.cx/Subscri...
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: www.cnbc.com/
Follow CNBC on LinkedIn: cnb.cx/LinkedI...
Follow CNBC News on Facebook: cnb.cx/LikeCNBC
Follow CNBC News on Twitter: cnb.cx/FollowCNBC
Follow CNBC News on Instagram: cnb.cx/Instagr...
www.cnbc.com/s...
#CNBC
#CNBCTV

[@scottiebumich]

Scam. Horrible pipeline and the later assets are in small indications with no real demand.

[@mattyfatstaxs]

U aren’t wrong

[@tzenmatteo]

yep

[@TrumpxDaily]

Wrong 😂

[@tzenmatteo]

@@TrumpxDaily shh

[@tzenmatteo]

incoming bubble

[@Bham67]

Talk is cheap. CEO can run his mouth and tell stories and prognosticate all day, but in the end, the proof is in the pudding. Recursion has no significant or consistent success stories. They are unprofitable and their losses increase each quarter. Dude needs to stop gloating over things he hasn't even done. Less talk, more action.